Browse our 650+ Publications​

Latest Publications

Clonal replacement of tumor-specific T cells following PD-1 blockade

Yost et al.
Nature Medicine
August 2019
Authors and Affiliates
Yost KE1, Satpathy AT2,3,4, Wells DK5, Qi Y1, Wang C6, Kageyama R5, McNamara KL7,8,9, Granja JM1,8,10, Sarin KY11, Brown RA12,11, Gupta RK13, Curtis C7,8,9, Bucktrout SL5, Davis MM5,14,15,16, Chang ALS17, Chang HY18,19,20,21,22; 1 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. 2 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. satpathy@stanford.edu. 3 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. satpathy@stanford.edu. 4 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. satpathy@stanford.edu. 5 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 6 iRepertoire Inc, Huntsville, AL, USA. 7 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. 8 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. 9 Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. 10 Program in Biophysics, Stanford University School of Medicine, Stanford, CA, USA. 11 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. 12 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 13 Stanford Biobank, Stanford University School of Medicine, Palo Alto, CA, USA. 14 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 15 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA. 16 Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. 17 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. alschang@stanford.edu. 18 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu. 19 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. howchang@stanford.edu. 20 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu. 21 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. howchang@stanford.edu. 22 Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu.

Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection

Vesely et al.
Cell
August 2019
Authors and Affiliates
Amezcua Vesely MC1, Pallis P2, Bielecki P2, Low JS2, Zhao J3, Harman CCD1, Kroehling L2, Jackson R2, Bailis W2, Licona-Limón P4, Xu H2, Iijima N2, Pillai PS5, Kaplan DH6, Weaver CT7, Kluger Y8, Kowalczyk MS9, Iwasaki A1, Pereira JP2, Esplugues E10, Gagliani N11, Flavell RA12.; 1 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. 2 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA. 3 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA. 4 Departamento de Biología Celular y del Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, México. 5 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Koch Institute for Integrative Cancer Research and Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. 6 Department of Dermatology and Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA. 7 Departments of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 8 Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA; Applied Mathematics Program, Yale University, New Haven, CT 06511, USA. 9 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 10 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Laboratory of Molecular and Cellular Immunology, Principe Felipe Research Center (CIPF), 46012 Valencia, Spain. 11 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; I. Medical Department and Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf 20246 Hamburg, Germany; Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden. Electronic address: n.gagliani@uke.de. 12 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. Electronic address: richard.flavell@yale.edu

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Khunger et al.
OncoImmunology
August 2019
Authors and Affiliates
Khunger A1, Rytlewski JA2, Fields P2, Yusko EC2, Tarhini AA3; 1 Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA. 2 Adaptive Biotechnologies, Seattle, WA, USA. 3 Department of Cutaneous Oncology, Moffitt Comprehensive Cancer Center, Tampa, Florida, USA.

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Ross et al.
Prostate Cancer and Prostatic Diseases
August 2019
Authors and Affiliates
Ross AE1, Hurley PJ2,3,4, Tran PT4,5,6, Rowe SP6, Benzon B2, Neal TO3,4, Chapman C3,4, Harb R3,4, Milman Y3,4, Trock BJ2,3,4, Drake CG7, Antonarakis ES2,3,4; 1 Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. ashley.ross@usoncology.com. 2 Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3 The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4 The Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5 The Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6 The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7 The Department of Medicine, Columbia University, New York, NY, USA.

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Shah et al.
Blood Advances
August 2019
Authors and Affiliates
Nirali N. Shah,1,* Haiying Qin,1,* Bonnie Yates,1 Ling Su,2 Haneen Shalabi,1 Mark Raffeld,3 Mark A. Ahlman,4 Maryalice Stetler-Stevenson,5 Constance Yuan,5 Shuang Guo,2 Siyuan Liu,2 Stephen H. Hughes,6 Terry J. Fry,1,7,8,† and Xiaolin Wu2,†; 1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 2Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; 3Molecular Diagnostics Section, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD; 4Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD; 5Flow Cytometry, Department of Pathology, NCI, NIH, Bethesda, MD; 6HIV Dynamics and Replication Program, NCI, NIH, Frederick, MD; 7Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO; and 8Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

Abraham et al.
Blood Advances
July 2019
Authors and Affiliates
Allistair A. Abraham,1,* Tami D. John,2,3,* Michael D. Keller,1 C. Russell N. Cruz,1 Baheyeldin Salem,1 Lauren Roesch,1 Hao Liu,4 Fahmida Hoq,1 Bambi J. Grilley,2,3 Adrian P. Gee,2,3 Hema Dave,1 David A. Jacobsohn,1 Robert A. Krance,2,3 Elizabeth. J. Shpall,2,3 Caridad A. Martinez,2,3 Patrick J. Hanley,1,† and Catherine M. Bollard1,† 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC; 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and 4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Palakurthi et al.
Cancer Immunology Research
July 2019
Authors and Affiliates
Palakurthi S#1, Kuraguchi M#1, Zacharek SJ#1, Zudaire E#2, Huang W1, Bonal DM3, Liu J1, Dhaneshwar A1, DePeaux K1, Gowaski MR1, Bailey D1, Regan SN1, Ivanova E1, Ferrante C2, English JM1, Khosla A4, Beck AH4, Rytlewski JA5, Sanders C5, Laquerre S2, Bittinger MA1, Kirschmeier PT1, Packman K2, Janne PA1,6, Moy C2, Wong KK1,7, Verona RI#8, Lorenzi MV8; 1 Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. 2 Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania. 3 Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts. 4 PathAI, Boston, Massachusetts. 5 Adaptive Biotechnologies, Seattle, Washington. 6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 7 Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, New York. 8 Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania. rverona@its.jnj.com mlorenzi@its.jnj.com. # Contributed equally

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor- induced encephalitis

Johnson et al.
Nature Medicine
July 2019
Authors and Affiliates
Johnson DB1,2, McDonnell WJ3,4,5,6,7, Gonzalez-Ericsson PI8, Al-Rohil RN5,9, Mobley BC5, Salem JE3,10, Wang DY3, Sanchez V5, Wang Y11, Chastain CA3, Barker K12, Liang Y12, Warren S12, Beechem JM12, Menzies AM13,14,15,16, Tio M13, Long GV13,14,15,16, Cohen JV17, Guidon AC17, O'Hare M17, Chandra S18, Chowdhary A18, Lebrun-Vignes B10, Goldinger SM19, Rushing EJ20, Buchbinder EI21, Mallal SA3,4,5,6,22, Shi C5, Xu Y11, Moslehi JJ3, Sanders ME5, Sosman JA23, Balko JM24,25,26,27; 1 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. douglas.b.johnson@vumc.org. 2 Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN, USA. douglas.b.johnson@vumc.org. 3 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 4 Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN, USA. 5 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 6 Center for Translational Immunology and Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA. 7 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. 8 Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN, USA. 9 Department of Pathology and Dermatology, Duke University Medical Center, Durham, NC, USA. 10 Sorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France. 11 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. 12 NanoString Technologies, Seattle, WA, USA. 13 Melanoma Institute Australia, Sydney, Australia. 14 The University of Sydney, Sydney, New South Wales, Australia. 15 Royal North Shore Hospital, Sydney, New South Wales, Australia. 16 Mater Hospital, Sydney, New South Wales, Australia. 17 Massachusetts General Hospital, Boston, MA, USA. 18 Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. 19 Department of Dermatology, University Hospital, Zurich, Switzerland. 20 Institute of Neuropathology, University Hospital, Zurich, Switzerland. 21 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 22 Institute for Immunology and Infectious Diseases, Perth, Australia. 23 Northwestern Feinberg School of Medicine, Chicago, IL, USA. 24 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org. 25 Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org. 26 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org. 27 Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN, USA. justin.balko@vumc.org.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Berner et al.
JAMA Oncology
July 2019
Authors and Affiliates
Fiamma Berner 1, David Bomze 2, Stefan Diem 2 3 4, Omar Hasan Ali 2 3 5 6, Mirjam Fässler 2 6, Sandra Ring 1 2, Rebekka Niederer 2 6, Christoph J Ackermann 3, Petra Baumgaertner 7, Natalia Pikor 2, Cristina Gil Cruz 2, Willem van de Veen 8 9, Mübeccel Akdis 8, Sergey Nikolaev 10 11, Heinz Läubli 12 13, Alfred Zippelius 12 13, Fabienne Hartmann 2, Hung-Wei Cheng 2, Gideon Hönger 14 15 16, Mike Recher 17, Jonathan Goldman 18, Antonio Cozzio 6, Martin Früh 3 19, Jacques Neefjes 20, Christoph Driessen 2 3, Burkhard Ludewig 2, Ahmed N Hegazy 21 22, Wolfram Jochum 23, Daniel E Speiser 7, Lukas Flatz 2 3 5 6; 1Microbiology and Immunology PhD Program, University of Zurich, Zurich, Switzerland. 2Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland. 3Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland. 4Department of Oncology and Haematology, Spital Grabs, Grabs, Switzerland. 5Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 6Department of Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland. 7Department of Oncology, Ludwig Cancer Research, University of Lausanne, Lausanne, Switzerland. 8Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland. 9Christine Kühne - Center for Allergy Research and Education, Davos, Switzerland. 10Gustave Roussy Cancer Campus, Villejuif, France. 11University Paris 7, St Louis Hospital, Paris, France. 12Cancer Immunology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. 13Division of Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. 14Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland. 15HLA-Diagnostics and Immunogenetics, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 16Transplantation Immunology and Nephrology, Department of Biomedicine, University Basel, Basel, Switzerland. 17Immunodeficiency Clinic and Immunodeficiency Lab, Medical Outpatient Unit and Department Biomedicine, University Hospital Basel, Basel, Switzerland. 18David Geffen School of Medicine, Department of Medicine, UCLA (University of California, Los Angeles), Ronald Reagan UCLA Medical Center, Santa Monica. 19University of Bern, Bern, Switzerland. 20Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. 21Medical Department for Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 22Berlin Institute of Health, Berlin, Germany. 23Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland.
Previous Next